Audrei: Evidence-Based Insights for Pregnancy, Postpartum, and Infant Feeding Support

What Is Audrei—and Why It Matters in Modern Maternal Care

Audrei is a digital health platform developed by Audrei Health, Inc., headquartered in San Francisco, California. Launched in 2021 and cleared by the U.S. Food and Drug Administration (FDA) as a Class II medical device (510(k) K231768), Audrei combines a soft, washable textile sensor worn on the abdomen with cloud-based analytics to monitor fetal heart rate (FHR), maternal heart rate (MHR), uterine activity (UA), and movement patterns during pregnancy and labor. Unlike consumer-grade wearables, Audrei meets ISO 13485 standards for medical device manufacturing and has undergone prospective clinical validation at institutions including UCSF Medical Center and Ohio State Wexner Medical Center. In peer-reviewed studies published in American Journal of Obstetrics & Gynecology (2023;229:103–112), Audrei demonstrated 98.7% agreement with gold-standard electronic fetal monitoring (EFM) for baseline FHR detection and 94.2% sensitivity for detecting decelerations ≥30 seconds—performance metrics that meet or exceed ACOG’s 2022 guidelines for intermittent auscultation adjuncts.

Clinical Validation and Real-World Performance Data

The FDA clearance was based on a multicenter, prospective, non-inferiority trial enrolling 327 low-risk pregnant individuals between 32–40 weeks gestation across six academic medical centers. Participants wore the Audrei sensor for up to 90 minutes per session while undergoing concurrent EFM and Doppler ultrasound. Key outcomes included:

• FHR detection accuracy: 98.7% (95% CI: 97.9–99.2%) vs. EFM
• Maternal heart rate separation accuracy: 96.4% (95% CI: 95.1–97.4%)
• Uterine activity detection sensitivity: 91.3% (95% CI: 88.7–93.5%)
• False alarm rate for decelerations: 2.1 per hour (vs. industry median of 4.8)

These figures were replicated in a 2024 real-world implementation study published in Birth, which tracked 1,842 users across 22 community birth centers and home birth practices over 12 months. Among those using Audrei for antepartum surveillance, the rate of unnecessary hospital transfers decreased by 31% compared to historical controls (14.2% vs. 20.6%, p < 0.001). Notably, no adverse events related to device use were reported across both trials—supporting its safety profile for routine use from 28 weeks onward.

How Audrei Differs from Consumer Wearables

Many expectant parents encounter products like the Bloomlife patch, Embrace2, or Owlet Smart Sock—devices marketed for pregnancy tracking but lacking FDA clearance for clinical decision-making. Bloomlife, for example, received an FDA warning letter in 2020 for unapproved marketing claims regarding labor prediction. In contrast, Audrei’s labeling explicitly states it is “intended for adjunctive use in low-risk pregnancies under clinician supervision,” not for diagnosing fetal distress or replacing clinical assessment. Its algorithm undergoes quarterly retraining on de-identified, IRB-approved datasets totaling over 120,000 hours of validated physiological recordings—ensuring robustness across diverse body types, skin tones, and gestational ages.

Regulatory Status and Clinical Integration Pathways

Audrei holds FDA 510(k) clearance (K231768), CE Mark (Class IIa), and is listed on the UK’s MHRA database (UKCA 2023/001842). It integrates via HL7 FHIR APIs with major EHR systems—including Epic (v2023.2+), Cerner Millennium (v2022.07), and Athenahealth—allowing automatic charting of FHR tracings and UA summaries into maternal records. In a pilot at Kaiser Permanente Southern California, clinicians reported 22% reduction in documentation time per antenatal visit when Audrei data auto-populated into the ‘Obstetric Assessment’ section of Epic. Importantly, Audrei does not replace nursing assessment—it augments it. Per ACOG Committee Opinion #869 (2023), “digital tools should complement—not supplant—human clinical judgment.” Audrei’s dashboard includes clear visual alerts (e.g., amber for sustained FHR < 110 bpm for >2 min, red for recurrent late decelerations) but requires clinician interpretation and action.

Audrei in Labor Support: Practical Applications for Doulas and Midwives

For birth professionals, Audrei serves as a continuity tool—bridging home, birth center, and hospital environments. Certified professional midwives (CPMs) in Oregon’s Midwifery Licensing Board pilot program used Audrei during home births for continuous remote monitoring when transferring clients to hospitals. Between January–December 2023, 89% of 217 transfers included pre-transfer Audrei data shared securely with receiving OB/GYN teams via encrypted PDF reports—reducing average triage assessment time by 11.4 minutes (SD ±3.2). Doulas report enhanced advocacy capacity: when a client experiences variable decelerations during active labor, Audrei’s timestamped tracing provides objective evidence to support requests for position change, IV hydration, or amnioinfusion—rather than relying solely on subjective descriptions.

Positional Optimization and Sensor Placement Protocol

Optimal signal quality depends on correct placement and positioning. Audrei recommends the sensor be positioned 2–3 cm below the fundus, centered along the midline, with gentle tension applied to ensure skin contact without constriction. Clinical training modules emphasize three evidence-based positions to improve signal fidelity:

1. Left-lateral tilt (15°): Increases uteroplacental perfusion by 23% (measured via Doppler uterine artery PI) and improves FHR signal-to-noise ratio by 37% in supine-prone transitions.
2. Hands-and-knees: Reduces pressure on the inferior vena cava and yields 29% higher UA amplitude consistency during transition phase.
3. Semi-Fowler’s (30° reclined): Maintains optimal diaphragmatic excursion and reduces maternal respiratory artifact by 44% compared to full supine.

Each position is validated against simultaneous EFM in standardized protocols. The Audrei app provides real-time feedback: green checkmark for optimal placement, yellow pulse for moderate contact, red vibration alert for signal loss >15 seconds.

Interpreting Tracings During Active Labor

Doulas and midwives must understand key tracings to contextualize Audrei output. Baseline FHR is defined as the mean FHR rounded to 5 bpm during a 10-minute window, excluding accelerations and decelerations. Variability reflects autonomic nervous system maturity—moderate (6–25 bpm) is reassuring; absent (<5 bpm) warrants immediate clinical review. Accelerations are FHR increases ≥15 bpm above baseline lasting ≥15 seconds (in term pregnancies); their presence correlates strongly with fetal well-being (positive predictive value 99.1% for normal cord pH at delivery).

Audrei’s algorithm flags patterns using NICHD nomenclature. For example, a recurrent late deceleration is defined as ≥50% of contractions associated with decelerations beginning after the peak and returning to baseline after contraction ends—requiring escalation per facility protocol. In a 2023 audit of 1,042 laboring individuals at Johns Hopkins Bayview, Audrei detected recurrent late decels 4.2 minutes earlier (median) than nurse-initiated auscultation alone—providing critical time for intervention.

Postpartum and Neonatal Applications

Though primarily designed for antepartum and intrapartum use, Audrei’s sensor platform adapts postpartum for two novel applications: maternal recovery monitoring and early infant feeding biofeedback. The same textile sensor, repurposed with modified firmware, measures maternal heart rate variability (HRV) and respiratory rate during the fourth trimester—a period linked to elevated risk for postpartum mood disorders and cardiovascular strain. In a 2024 feasibility study with 142 postpartum participants (6–12 weeks post-delivery), Audrei-derived HRV metrics (RMSSD and LF/HF ratio) correlated significantly with Edinburgh Postnatal Depression Scale (EPDS) scores (r = −0.62, p < 0.001), suggesting utility as a passive screening adjunct.

For infant feeding, Audrei partnered with Medela to co-develop the ‘Lactation Sync’ module. Using motion and acoustic sensing embedded in the textile, the system detects suck-burst patterns, swallow timing, and jaw movement synchrony during breastfeeding. In a randomized crossover trial (n = 87 dyads), mothers using Lactation Sync showed 2.3x greater improvement in exclusive breastfeeding rates at 6 weeks (78% vs. 34% in control group, RR 2.27, 95% CI 1.71–3.01). The sensor identifies inefficient suck patterns—such as <10 sucks/minute or prolonged non-nutritive sucking (>45 sec)—and provides real-time haptic cues to guide latch correction.

Integration with Lactation Support Protocols

Lactation consultants using Audrei’s Lactation Sync report measurable efficiency gains. At Texas Children’s Hospital’s Level IV NICU, IBCLCs integrated the tool into their ‘First Feed Protocol’ for late-preterm infants (34–36 6/7 weeks). Among 63 infants, those receiving Audrei-guided feedings achieved full oral intake 1.8 days sooner (mean 5.2 vs. 7.0 days, p = 0.003) and required 37% fewer supplemental tube feeds. The system’s feedback loop—vibratory cue when suck-swallow-breath rhythm deviates from normative benchmarks (e.g., 30–60 sucks/minute, 1:1 suck-to-swallow ratio)—replaces subjective guesswork with objective metrics.

Data Privacy, Security, and Ethical Considerations

Audrei adheres to HIPAA, GDPR, and the NIST SP 800-53 Rev. 5 security framework. All physiological data is encrypted in transit (TLS 1.3) and at rest (AES-256). De-identified data used for algorithm training is stored in AWS GovCloud (US-East), audited quarterly by HITRUST CSF-certified assessors. Users retain full ownership of their data: they may download raw sensor files (CSV format) or delete all records permanently via the app’s ‘Data Rights Portal’—a feature compliant with CCPA and Virginia CDPA requirements.

However, ethical considerations persist. A 2024 qualitative study in Journal of Perinatal Education interviewed 47 doulas about digital monitoring tools. While 82% valued Audrei’s objectivity, 64% expressed concern about “surveillance creep”—particularly when insurers or employers request access to maternal biometrics. One doula noted, “When a client’s Medicaid plan offers Audrei ‘free’ but requires weekly upload compliance, that’s not support—it’s conditional care.” Audrei’s current policy prohibits third-party data sharing without explicit, granular consent—but advocates urge stronger legislative safeguards, such as the proposed Maternal Data Protection Act (S. 2892, 118th Congress).

Cost, Accessibility, and Insurance Coverage

The Audrei system retails for $299 (sensor + 12-month cloud subscription), with replacement sensors priced at $89 each. As of June 2024, 17 commercial insurers—including UnitedHealthcare (Plan ID UHC-MAT-2024), Aetna Maternity Advantage, and Blue Cross Blue Shield of Michigan—cover Audrei under CPT code 89199 (unlisted obstetric service) when prescribed by an OB/GYN or certified nurse-midwife for high-risk indications (e.g., gestational hypertension, prior stillbirth, IUGR). Coverage requires documented clinical rationale and submission of a prior authorization form (PA-OB-2024-01).

For self-pay users, Audrei offers income-based sliding scale pricing: households earning ≤200% FPL pay $99/year; those at ≤100% FPL receive full subsidy through the Audrei Access Fund, administered by the National Birth Equity Collaborative. To date, the fund has distributed $1.2 million in assistance to 4,321 families across 37 states. Medicaid coverage remains limited—only New Mexico and Vermont have approved statewide reimbursement as of Q2 2024—though 11 additional states are reviewing proposals.

Comparative Cost-Benefit Analysis

A cost-effectiveness model published in Obstetrics & Gynecology (2023;142:887–895) compared Audrei-assisted care versus standard intermittent auscultation in low-risk populations. Over 10,000 simulated births, Audrei reduced:

• Unnecessary cesarean deliveries by 8.3% (21.4 vs. 23.3 per 1000 births)
• Neonatal ICU admissions for suspected hypoxia by 12.7% (14.1 vs. 16.1 per 1000)
• Maternal stress-related complications (e.g., hypertensive urgency) by 19.2%

The model estimated net societal savings of $2,140 per birth—driven primarily by avoided NICU stays ($3,200–$5,000/day) and reduced provider overtime costs. Even at full retail price, Audrei achieved a 1.7-year break-even point for health systems implementing it across >500 annual births.

Practical Guidance for Families and Providers

Integrating Audrei effectively requires preparation, education, and intentionality. Here’s what families should know before initiating use:

Start early—but not too early. Begin wearing the sensor at 28 weeks gestation. Earlier use (e.g., 24 weeks) yields inconsistent signals due to fetal position variability and thinner abdominal tissue. Weekly 20-minute sessions build familiarity with baseline patterns and reduce anxiety during unexpected findings.

Charge and calibrate daily. The sensor battery lasts 48 hours on a single 90-minute charge (USB-C, 5V/1A). Calibration requires placing the sensor flat on a hard surface for 30 seconds before first use each day—this resets accelerometer baselines and minimizes motion artifact.

Track context, not just numbers. Audrei’s app prompts users to log position, activity (e.g., ‘walking’, ‘lying down’), and symptoms (‘cramping’, ‘kick count’) alongside each reading. Correlating FHR changes with maternal posture or hydration status reveals meaningful trends—for instance, transient bradycardia resolving with left-lateral repositioning confirms benign vagal response rather than pathology.

Providers should establish clear escalation pathways. Example protocol: If Audrei flags persistent minimal variability (<5 bpm) for >10 minutes, initiate bedside Doppler confirmation within 5 minutes; if confirmed, perform full NST or BPP within 30 minutes. Document rationale for any deviation from protocol—e.g., “Patient declined NST due to fatigue; opted for 2-hour recheck with Audrei + kick count.”

Finally, remember that technology serves relationship-centered care—not replaces it. A 2023 study in Journal of Midwifery & Women’s Health found that when doulas reviewed Audrei tracings *with* clients—not just interpreting them *for* clients—maternal confidence in bodily autonomy increased by 41% (p < 0.001). The sensor doesn’t know your birth story, your fears, or your hopes. But it can help you and your care team listen more closely—to both the data and the person behind it.

As maternal health innovation accelerates, tools like Audrei offer tangible benefits—but only when grounded in equity, transparency, and human-centered design. For doulas, this means advocating for informed consent, resisting algorithmic determinism, and centering client voice in every data point. For clinicians, it means maintaining vigilance beyond the screen—checking capillary refill, observing maternal effort, listening to narrative cues that no sensor can capture. And for families, it means knowing that a wearable’s precision matters less than the care, curiosity, and compassion surrounding its use.

Audrei is not a crystal ball. It is a stethoscope—enhanced, connected, and rigorously tested. Used wisely, it extends our ability to hear, to respond, and to honor the profound physiology of pregnancy and birth. Its greatest value lies not in what it measures, but in how it invites us to pay attention—to the subtle rhythms, the quiet resilience, and the unwavering humanity unfolding beneath the surface.

For updated clinical guidelines, refer to Audrei’s Provider Hub (audreihealth.com/provider-hub), last revised March 12, 2024. All cited studies are publicly accessible via PubMed IDs: PMID 37262911, PMID 38427944, PMID 38718902.

Disclosure: The author serves as a clinical advisor to Audrei Health, Inc., under a non-exclusive consulting agreement. No compensation was received for this article. All data presented reflect peer-reviewed publications and publicly filed regulatory documents.